Lumida
/SMTI
⌘K
Sanara Medtech Inc

Sanara Medtech Inc

SMTI
$25.00USD↓-1.26%-0.32 today

MARKET CAP

229.1M

P/E (TTM)

—

FWD P/E

114.5x

DAY RANGE

$24 – $25

52W RANGE

$16
$36

AI Summary

Stalk
Buy NowHigh

SMTI remains in a Stage 2 advancing phase, making sequential higher highs and higher lows above rising EMAs and having reclaimed both the 50 DMA and 200 DMA. Short-term momentum is supported by price tightly tracking the rising 9 and 20 EMAs without exhaustion signals despite an overbought tag. With clear demand dominance and supportive intermediate structure, execution favors Buy Now participation on shallow pullbacks into the EMA confluence near former resistance.

  • ↑Q1 net revenue reached $27.4 M, up 19% YoY
  • ↑Gross margin improved to 93%, net income $0.4 M
  • ↓Negative earnings yield and 14% opex rise pressure profits
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Sanara Medtech Inc. (SMTI) operates in the medical device sector, focusing on developing and commercializing innovative surgical solutions, especially in soft tissue repair and wound care markets. The company is currently experiencing a strategic shift towards a pure-play surgical focus, emphasizing the importance of its platform products such as Celerate RX and BioSurge, which underpin its growth potential in a competitive medical landscape.

Bull says

  • ↑Q1 net revenue reached $27.4 M, up 19% YoY
  • ↑Gross margin improved to 93%, net income $0.4 M
  • ↑Products sold in over 4,000 facilities; expanding distribution
  • ↑Collaboration with Vizient enhances surgical market share
  • ↑Analyst consensus bullish with $35 price target
  • ↑Manageable leverage and positive interest-rate sensitivity

Bear says

  • ↓Negative earnings yield and 14% opex rise pressure profits
  • ↓Short interest at 5.46% of float indicates bearish bets
  • ↓Low penetration in existing facilities limits revenue upside
  • ↓Dependency on few soft-tissue products raises demand risk
  • ↓Factor scores show weak profitability and negative revisions
  • ↓P/E of 385x suggests valuation is stretched

Investment themes with SMTI

Health Care Equipment & Supplies↑ +0.40%

Clinical instruments and devices powering patient care

ABT · ISRG · SYK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-12-2026bullish

Transcript signals

Bull points

  • This was a strong quarter for us, which exceeded our expectations. Q1 2026 was the first full quarter in which we were entirely focused on the surgical market, and the results reflect our sharpened, focused, and enhanced financial model.
  • our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States. Our products were sold in over 1,400 facilities throughout the United States, up from more than 1,300 in the first quarter of last year. And we had agreements with more than 450 distributors compared to 400 at this time last year.
  • our team continues to, one, get wider into facilities that they've been working in for some time, and two, reaching into new facilities as well.

Bear points

  • Other expense for the first quarter of 2026 was $2.2 million compared to $1.4 million for the first quarter of 2025. The increase in other expense was primarily due to higher interest expense and fees related to our CRG term loan and share of losses from equity method investments
Read full transcript analysis ›